Rapport Therapeutics (RAPP) logo

Rapport Therapeutics (RAPP) stock

Neurological medicines , market cap $1.4B

$23.16
-1.82%

Why is RAPP down?

Down 53% in 3 months while the S&P 500 fell 10%.

  • It filed a prospectus for convertible notes of $150.0M on Oct 30, 2026, its newest of 3 offering filings.

Sources: Price history, Nov 20, 2026; Prospectus supplement, Oct 30, 2026

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time RAPP moves

Free account, no card. An optional alert when RAPP moves or its score changes.Pro, $1 for a first month. An optional alert when RAPP moves or its score changes.Pro, 7 days free with a card. An optional alert when RAPP moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on RAPP →1 more reason why RAPP is down, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-2
Poor
In its industry
#138of 273
Checks firing
3of 14
Trending down
From 52-week high
-56.2%
under its best in a year

RAPP's Quality Score was unchanged on Fri, Nov 20, at -2.

Follow RAPP's trial news. Pro members can get an alert when Rapport Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when RAPP files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…FOS open-label long-term safety extension of Phase 2a trial: Initial data expected in fourth quarter of 2026…”Trial data · SEC filing · Nov 4
Cash$395M, about 13 quarters (3.5 years) at the last year's spendingOn Sep 30 · raised money since, not counted · the company says “through the end of 2029”

Key facts on RAPP

Key facts on RAPP
Holding it back25.9% more shares than a year ago
Latest filing8-K, Nov 4 Reported its quarterly results

RAPP in the news

Big story

Tue Oct 20: Trial

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

RAPP closed +2.7% that day on 22.4x normal volume.

Reported by GlobeNewswire · covered by 11 outlets

Get an alert on RAPP's next big story →Get an alert on RAPP's next big story →Start Pro

Outlet counts from the GDELT Project. The move is what RAPP did that session, not a claim about why.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$395M, about 13 quarters (3.5 years) at the last year's spendingOn Sep 30 · raised money since, not counted · the company says “through the end of 2029”

RAPP catalysts

Coming up

After its last 4 reports it closed +1.8% on average, higher 3 of 4 times.

4 more coming up and 6 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for RAPP, and how long its cash lasts

Next step the company has named

Q4 2026“RAP-219 FOS open-label long-term safety extension of Phase 2a trial: Initial data expected in fourth quarter of 2026.”Trial data · SEC filing · Nov 4

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
RAP-219 · Focal Seizure · Phase 3
Its trial
FOCUS 1Phase 3 · Recruiting · 333 people · main data estimated Jul 2029 · NCT07563881

3 more trials, 5 more milestones and 24 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 13 quarters

$395M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “through the end of 2029” (8-K, Nov 4). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Mar 10, 2026)
  • At-the-market share sales program (S-3ASR, filed Mar 10, 2026)

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

Director James Healy bought 969,480 shares on Oct 28. 29 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Abraham Ceesay’s 17 filings and quotes.

Get an alert when RAPP files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How RAPP ranks in Biotech

RAPP is #138 of 273 by Quality Score.

How RAPP ranks in Biotech
RankStockQuality Score
138Rapport Therapeutics (RAPP) logoRAPPRapport Therapeutics-2

More in Biotech

When does RAPP report earnings, and what happens after?

Expected to report Tue Mar 9, before the open (in 108 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What RAPP reported on Nov 4, 2026

The quarter

A loss of $0.84 a share, from $0.71.

“The increase in R&D expense was primarily driven by operational costs related to clinical development of RAP-219, including the Phase 3 FOS program and completion of the bipolar mania Phase 2 trial, and costs to support the progression of the Company’s overall pipeline.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

RAPP's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase in SG&A was primarily driven by costs associated with the growth of the business, including an increase in headcount and related compensation.”

From its results filing (SEC filing · Nov 4)

The numbers

Market value
$1.4B
today
Free cash flow
-$121M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on RAPP: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+7.7%+0.6%+1.9%
May 7Aug 5Nov 4
ReportedGapReaction5
days
Nov 4, 2026Before open+2.7%+1.9%+2.0%
Aug 5, 2026Before open-1.8%+0.6%+15.7%
May 7, 2026Before open+1.2%+7.7%+2.8%

RAPP closed higher after 3 of its last 4 reports.

All 4 reports, and RAPP's Quality Score going into each

RAPP has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on RAPP, and all 14 on every stock.Get in free →See the top 3 →Start Pro

RAPP RSI on Nov 20: 37.2, below its 50-day and 200-day averages

Not scored

RSI 37.2, MACD above signal, below both averages. Not scored.

The deep dive on RAPP

6 more findings on RAPP, each with its source, for Pro members.

RAPP share count over time

26% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of RAPP outstanding, as filed
Shares
outstanding
As
of
59.3MNov 2, 2026
48MAug 3, 2026
47.8MMay 4, 2026
47.8MMar 2, 2026
Offerings, shelves, and splits of RAPP, from its filings
From its
filings
Filed
Sold $150M of convertible notes, about 11% of its market valueOct 30, 2026
Priced a sale of sharesOct 30, 2026
Registered shares for a later sale (S-3ASR)Mar 10, 2026
Set up an at-the-market program for up to $110M of shares, about 8% of its market valueJan 7, 2026

4 more offerings on file, for Pro members.

RAPP insider trades

6 insiders bought $1.7M across 7 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyRamiro Sanchez$98KDirectorat $27.35 on Oct 23, filed Oct 23

All 7 insider filings on RAPP from the last six months, for Pro members.

All RAPP insider trades

4 more buys of RAPP in the last three months are not counted as insider buys. Bought at a price outside that day's trading, so not on the market that day.

RAPP's officers and directors

Officers and directors with a Form 4 in the last 12 months.

3 more officers and directors file at RAPP.

See insider trades by person

Which ETFs hold RAPP?

In ETFs: RAPP is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

84 employeesBoston, MArapportrx.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on RAPP and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn RAPP's score around: 8 things
  • 11 more filings explained, a plain line each
  • 4 more things pulling RAPP's score down
BreakawayOct 23Ramiro Sanchez bought RAPP$98K at $27.35, filed Oct 23

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: RAPP's Quality Score is -2 (Poor), #138 of 273 in Biotech. Insiders bought $1.7M in the last 6 months (Form 4).

What does RAPP's Quality Score say?

RAPP scores -2 today, which Breakaway calls Poor. It is #138 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 53% in 3 months while the S&P 500 fell 10%. Cash lasts about 13 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is RAPP's Quality Score?

RAPP scores -2 today, which Breakaway calls Poor (below zero). That is #138 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RAPP's -2.

Are insiders buying RAPP?

6 insiders bought $1.7M across 7 filings in the last 6 months. No open-⁠market sales on record. The newest is Ramiro Sanchez, Director, who bought $98K on Oct 23. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Rapport Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.